Dose escalation is the step-by-step increase of the dose of an investigational medicinal product in a clinical trial according to predefined decision criteria. It is used primarily in first-in-human and other early trials to investigate exposure, tolerability, pharmacodynamic effects and initial activity across multiple dose levels. Its purpose is a traceable and risk-conscious further development of the dose, not merely reaching the highest dose.<\/p>\n
The protocol must describe the derivation of the starting dose, the intended dose range or the maximum exposure as well as the criteria for dose increases. The EMA guideline on first-in-human and early clinical trials additionally requires decision rules for adjustments based on the data emerging during the course of the trial. Relevant are the available non-clinical information on pharmacology, toxicology, pharmacokinetics and toxicokinetics as well as the associated uncertainties.<\/p>\n
The dose levels must not be planned disconnected from the expected exposure. In the case of known or suspected steep dose-, exposure-response or exposure-toxicity relationships, smaller steps are indicated. This applies in particular if serious effects can occur without a easily recognizable precursor. In oncological trials, ICH S9 requires the starting dose to be scientifically justified with all available non-clinical data; given a steep relationship to severe toxicity, smaller than usual dose increments should be considered.<\/p>\n
Usually, consecutive cohorts receive different dose levels. Rule-based and model-informed designs can be used for this; it is crucial that the rules are clearly described in the protocol and consistently applied during trial operations. Before proceeding to the next dose level, the specified data and observation periods are evaluated. This includes adverse events, clinical examinations, laboratory values as well as, if provided, PK and PD data.<\/p>\n
In the case of multiple dosing, it must be particularly considered whether drug concentrations accumulate or delayed effects occur. The observation period between dose levels must therefore be appropriate to the mechanism of action, the expected kinetics and the identified risk profile.<\/p>\n
Dose-limiting toxicities are events or findings defined in the protocol that influence further dose development within a specified observation window. They are an important decision element, but not the only basis. The protocol should also contain stopping rules for individual participants, a cohort and the entire trial as well as the required time intervals and data for escalation decisions. If criteria are changed outside the authorized framework, the regulatory classification of a substantial modification must be assessed.<\/p>\n
The maximum tolerated dose, MTD, is an outcome parameter: it designates a dose that is still considered tolerated under the previously determined conditions. Dose escalation, on the other hand, is the prospective process by which dose levels are investigated sequentially and safety information is obtained. In some programs, especially for targeted agents, the MTD is not the sole or decisive basis for further dose selection.<\/p>\n
Dose finding is broader than dose escalation. It encompasses the entirety of the investigations that justify a suitable dose and a suitable regimen for a defined patient group, including exposure-response analyses, multiple dose arms or subsequent dose optimization trials. The escalation provides early data for this; the recommended dose for subsequent trials results from an integrated assessment of safety, PK, PD and \u2013 if available \u2013 clinical activity.<\/p>\n
A dose escalation requires robust operational procedures, because decisions are often only possible after the timely consolidation of heterogeneous data. Investigational sites must unambiguously document dose level, treatment dates, safety observations and sample time windows. The sponsor must ensure that the expected benefits justify the foreseeable risks and burdens and that this condition is continuously monitored. Delayed safety data, inconsistent assessments or errors in the preparation and dispensing of different strengths can impair the protection of the participants and the validity of the dose decision.<\/p>\n
Full-service CROs such as Mediconomics support with the operational implementation of escalation plans through project management, investigational site management, monitoring, safety data processes and data management. They coordinate the timely recording of laboratory, PK and tolerability data, prepare documents for documented safety reviews and support the follow-up of protocol specifications, medicinal product logistics and, if applicable, regulatory changes.<\/p>\n
What is the choice of the next dose level based on?<\/strong><\/p>\n It is based on the criteria defined in the protocol and on the entirety of the available data. This can include safety findings, observed exposure, pharmacodynamic effects and non-clinical evidence.<\/p>\n Is the highest investigated dose automatically the recommended dose?<\/strong><\/p>\n No. The selection of a recommended dose is based on the benefit-risk assessment and can lie below the highest or maximum tolerated dose.<\/p>\n Why are PK data important during a dose escalation?<\/strong><\/p>\n They show which exposure is actually achieved after a dose. This allows non-linear increases, unexpectedly high concentrations and the relationship between exposure, effect and safety to be recognized.<\/p>\n Dose escalation is the step-by-step increase of the dose of an investigational medicinal product in a clinical trial according to predefined decision criteria. It is used primarily in first-in-human and other early trials to investigate exposure, tolerability, pharmacodynamic effects and initial activity across multiple dose levels. Its purpose is a traceable and risk-conscious further development […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6921","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6921","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":2,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6921\/revisions"}],"predecessor-version":[{"id":7505,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6921\/revisions\/7505"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6921"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6921"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory references<\/h2>\n
\n